Poliomyelitis - Pipeline Review, H2 Pharmaceutical 2016
Albany, New York, Jan 17,2017
"Poliomyelitis
- Pipeline Review, H2 2016"
The Report covers current Industries Trends, Worldwide Analysis,
Global Forecast, Review, Share, Size, Growth, Effect.
Description-
Global
Markets Direct's latest Pharmaceutical and Healthcare disease
pipeline guide Poliomyelitis Pipeline Review, H2 2016, provides an
overview of the Poliomyelitis (Infectious Disease) pipeline
landscape.
Polio
is a highly infectious disease caused by a virus. It invades the
nervous system, and causes total paralysis in a matter of hours.
Symptoms include fever, fatigue, headache, vomiting, stiffness in the
neck and pain in the limbs. Preventive measures such as the use of
vaccines are effective for polio.
*
Report Highlights
Global
Markets Direct's Pharmaceutical and Healthcare latest pipeline guide
Poliomyelitis Pipeline Review, H2 2016, provides comprehensive
information on the therapeutics under development for Poliomyelitis
(Infectious Disease), complete with analysis by stage of development,
drug target, mechanism of action (MoA), route of administration (RoA)
and molecule type. The guide covers the descriptive pharmacological
action of the therapeutics, its complete research and development
history and latest news and press releases.
The
Poliomyelitis (Infectious Disease) pipeline guide also reviews of key
players involved in therapeutic development for Poliomyelitis and
features dormant and discontinued projects. The guide covers
therapeutics under Development by Companies /Universities
/Institutes, the molecules developed by Companies in Filing
rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and
Discovery stages are 1, 7, 3, 2, 5 and 7 respectively. Similarly, the
Universities portfolio in Phase II and Discovery stages comprises 2
and 1 molecules, respectively.
Poliomyelitis
(Infectious Disease) pipeline guide helps in identifying and tracking
emerging players in the market and their portfolios, enhances
decision making capabilities and helps to create effective counter
strategies to gain competitive advantage. The guide is built using
data and information sourced from Global Markets Directs proprietary
databases, company/university websites, clinical trial registries,
conferences, SEC filings, investor presentations and featured press
releases from company/university sites and industry-specific third
party sources. Additionally, various dynamic tracking processes
ensure that the most recent developments are captured on a real time
basis.
*
Scope
-
The pipeline guide provides a snapshot of the global therapeutic
landscape of Poliomyelitis (Infectious Disease).
-
The pipeline guide reviews pipeline therapeutics for Poliomyelitis
(Infectious Disease) by companies and universities/research
institutes based on information derived from company and
industry-specific sources.
-
The pipeline guide covers pipeline products based on several stages
of development ranging from pre-registration till discovery and
undisclosed stages.
-
The pipeline guide features descriptive drug profiles for the
pipeline products which comprise, product description, descriptive
licensing and collaboration details, R&D brief, MoA & other
developmental activities.
-
The pipeline guide reviews key companies involved in Poliomyelitis
(Infectious Disease) therapeutics and enlists all their major and
minor projects.
-
The pipeline guide evaluates Poliomyelitis (Infectious Disease)
therapeutics based on mechanism of action (MoA), drug target, route
of administration (RoA) and molecule type.
-
The pipeline guide encapsulates all the dormant and discontinued
pipeline projects.
-
The pipeline guide reviews latest news related to pipeline
therapeutics for Poliomyelitis (Infectious Disease)
*
Reasons to buy
-
Procure strategically important competitor information, analysis, and
insights to formulate effective R&D strategies.
-
Recognize emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive
advantage.
-
Find and recognize significant and varied types of therapeutics under
development for Poliomyelitis (Infectious Disease).
-
Classify potential new clients or partners in the target demographic.
-
Develop tactical initiatives by understanding the focus areas of
leading companies.
-
Plan mergers and acquisitions meritoriously by identifying key
players and its most promising pipeline therapeutics.
-
Formulate corrective measures for pipeline projects by understanding
Poliomyelitis (Infectious Disease) pipeline depth and focus of
Indication therapeutics.
-
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
-
Adjust the therapeutic portfolio by recognizing discontinued projects
and understand from the know-how what drove them from pipeline.
Comments
Post a Comment